Results 251 to 260 of about 134,039 (317)

Are Conscientious Refusal and Conscientious Provision Mutually Exclusive? A Critique of Kelusa and Giubilini's Argument

open access: yesBioethics, EarlyView.
ABSTRACT This article challenges the claim that conscientious refusal and conscientious provision in healthcare are mutually exclusive and thus asymmetrical. While US law protects healthcare providers who refuse to perform medical services on moral or religious grounds, it offers no equivalent protections to those who feel morally compelled to provide ...
Tzofit Ofengenden
wiley   +1 more source

Inequities in Care During Pregnancy Loss: Empirical Insights From Experiences With Canadian Perinatal Care

open access: yesBirth, EarlyView.
Inequities in Canadian Care during Pregnancy Loss. ABSTRACT Background Individuals experiencing perinatal loss are entitled to respectful maternity care, but a paucity of research examines respectful care at the time of pregnancy loss. Method We used data from an online cross‐sectional survey (July 2020–February 2022), where 172 individuals reported on
Wendy A. Hall   +5 more
wiley   +1 more source

A novel index to measure pre‐planning in the Tower of London task: Test–retest reliability and known‐group validity

open access: yesBritish Journal of Psychology, EarlyView.
Abstract The Tower of London (TOL) is a planning task frequently used in clinical settings and research. Planning and execution times are the most common outcome variables despite yielding lower effect sizes in clinical group comparisons and lower test–retest reliability than planning accuracy. Here, it is proposed that planning time be analysed not in
Lena V. Schumacher   +5 more
wiley   +1 more source

HIV and induced abortion among migrants from sub-Saharan Africa living in Île-de-France: Results of the PARCOURS study. [PDF]

open access: yesJ Migr Health
Pilecco FB   +4 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Unraveling the Genetic Mysteries of Müllerian Anomalies: Research Approaches and Clinical Significance

open access: yesClinical Genetics, EarlyView.
This review primarily summarizes the genetic defects in Müllerian anomalies, the tools used to validate these genetic defects, and the future clinical significance of identifying the precise genetic etiology of Müllerian anomalies. ABSTRACT Müllerian anomalies are a collection of heterogeneous anatomical disorders of the female genital tract that ...
Jingfang Li   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy